<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003575</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02276</org_study_id>
    <secondary_id>AMC-008</secondary_id>
    <secondary_id>CDR0000066642</secondary_id>
    <nct_id>NCT00003575</nct_id>
  </id_info>
  <brief_title>Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Randomized Pre-Phase II Trial of Interleukin-2, Interleukin-12, or No Additional Therapy Following Response to Ifosfamide/Etoposide Chemotherapy for Refractory HIV-Associated Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to compare the effectiveness of interleukin-12 following chemotherapy in&#xD;
      treating patients who have refractory HIV-associated non-Hodgkin's lymphoma. Drugs used in&#xD;
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by&#xD;
      stimulating a person' white blood cells to kill cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy of interleukin-12 (IL-12) by evaluating its effect on remission&#xD;
      duration after response to second line chemotherapy with ifosfamide and etoposide in patients&#xD;
      with HIV-associated non-Hodgkin's lymphoma.&#xD;
&#xD;
      II. Determine the safety of IL-12 when administered as maintenance therapy in these patients.&#xD;
&#xD;
      III. Evaluate overall survival of this patient population. IV. Evaluate serum and tissue&#xD;
      cytokine levels in these patients. V. Evaluate the effect of IL-12 on HIV viral load and on&#xD;
      functional T-cell assays in these patients.&#xD;
&#xD;
      VI. Evaluate the effect of IL-12 on Epstein-Barr Virus (EBV) viral load in these patients.&#xD;
&#xD;
      OUTLINE: This is an open label study.&#xD;
&#xD;
      All patients receive ifosfamide IV by continuous infusion for 2 days, etoposide IV over 2&#xD;
      hours daily on days 1 and 2, and filgrastim (G-CSF) subcutaneously (SC) daily on days 4-13.&#xD;
      Courses are repeated every 21 days. Patients who have complete or partial remission after a&#xD;
      minimum of 4 courses of chemotherapy receive maintenance therapy consisting of interleukin-12&#xD;
      SC twice weekly beginning on day 28 of the final chemotherapy course and continuing for 6&#xD;
      months or until disease progression. All patients also receive combination antiretroviral&#xD;
      therapy during study.&#xD;
&#xD;
      Patients are followed every month for one year, then every 2 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <primary_completion_date type="Actual">April 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients receive ifosfamide IV by continuous infusion for 2 days, etoposide IV over 2 hours daily on days 1 and 2, and filgrastim (G-CSF) subcutaneously (SC) daily on days 4-13. Courses are repeated every 21 days. Patients who have complete or partial remission after a minimum of 4 courses of chemotherapy receive maintenance therapy consisting of interleukin-12 SC twice weekly beginning on day 28 of the final chemotherapy course and continuing for 6 months or until disease progression. All patients also receive combination antiretroviral therapy during study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interleukin-12</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  HIV-infected patients with histologically or cytologically proven intermediate grade&#xD;
             large cell lymphoma; high grade large cell immunoblastic lymphoma; or high grade small&#xD;
             noncleaved cell lymphoma who have either failed to respond to or relapsed following&#xD;
             first line combination chemotherapy&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
          -  No CNS lymphoma (parenchymal brain or spinal cord tumor)&#xD;
&#xD;
          -  No meningeal lymphoma&#xD;
&#xD;
          -  A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ.&#xD;
             The terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former&#xD;
             terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol&#xD;
             uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Age: 18 to 70&#xD;
&#xD;
          -  Performance status: Karnofsky 60-100%&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm3&#xD;
&#xD;
          -  Platelet count greater than 75,000/mm3&#xD;
&#xD;
          -  Hematologic criteria not applicable if abnormal functions are attributable to&#xD;
             lymphomatous infiltration of bone marrow or liver&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL, except in patients receiving indinavir who have&#xD;
             isolated hyperbilirubinemia&#xD;
&#xD;
          -  Transaminases less than 5 times upper limit of normal&#xD;
&#xD;
          -  Hepatic criteria not applicable if abnormal functions are attributable to lymphomatous&#xD;
             infiltration of bone marrow or liver&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
          -  No other prior or concurrent malignancy except carcinoma in situ of the cervix or&#xD;
             nonmetastatic nonmelanomatous skin cancer&#xD;
&#xD;
          -  No acute active opportunistic infection requiring antibiotic treatment Patients with&#xD;
             Mycobacterium avium complex allowed&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 2 weeks since prior immunomodulating agents&#xD;
&#xD;
          -  Concurrent filgrastim (G-CSF) allowed&#xD;
&#xD;
          -  Concurrent epoetin alfa allowed&#xD;
&#xD;
          -  Concurrent antibiotics may be given if clinically indicated during study&#xD;
&#xD;
          -  No more than 2 prior standard treatment regimens for non-Hodgkin's lymphoma&#xD;
&#xD;
          -  No concurrent systemic corticosteroids&#xD;
&#xD;
          -  Concurrent topical and/or oral antifungal agents permitted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence D. Kaplan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-0800</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco General Hospital Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvester Cancer Center, University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital/New Jersey Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital - Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2002</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2004</study_first_posted>
  <last_update_submitted>February 7, 2013</last_update_submitted>
  <last_update_submitted_qc>February 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related diffuse large cell lymphoma</keyword>
  <keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
  <keyword>AIDS-related small noncleaved cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Interleukin-12</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

